March 12th, 2019 | NewsPharmacy Pearls

This month, we are releasing an AHP quality improvement initiative for ADHD in patients ≤21 years of age. Recognizing that ADHD is complicated in terms of diagnosis, the impact of comorbidities, and multiple available treatment options, we have chosen to initially focus on rates of pediatric ADHD diagnosis and network-wide prescribing patterns of stimulant medications…

Read More ›

February 19th, 2019 | Clinical ConnectionsPharmacy Pearls

The AHP Pharmacy Task Force works to identify opportunities that will enhance the quality, safety and value of medication treatment for our patients. Recently, we identified a cohort of patients across the PCN on duplicate therapy for Type 2 Diabetes with a GLP-1 agonist (e.g., Victoza, Trulicity, Byetta, Bydureon) and a DPP-4 inhibitor (e.g., Januvia,…

Read More ›

January 11th, 2019 | NewsPharmacy Pearls

This edition of Pharmacy Pearls reviews the new drug baloxavir (Xofluza) and its role in therapy compared to other oral antiviral agents for the treatment of influenza based on currently published data and CDC treatment recommendations.

November 13th, 2018 | NewsPharmacy Pearls

As a reminder, November 12-18, 2018 is U.S. Antibiotic Awareness Week. The CDC is urging healthcare professionals to prescribe antibiotics only when necessary to help fight antibiotic resistance and protect patients from adverse events. During U.S. Antibiotic Awareness Week the CDC promotes Be Antibiotics Aware, an educational effort to raise awareness about the importance of…

Read More ›

September 25th, 2018 | Pharmacy Pearls

This edition of Pharmacy Pearls reviews the available basal insulin products with regards to cost and side effects to consider when selecting an agent for a patient. Additionally, we have included guidance for switching between insulin products and review recently published literature that shows that NPH insulin is noninferior to basal insulin analogs. Finally, we…

Read More ›

August 2nd, 2018 | Clinical ConnectionsPharmacy Pearls

Starting at the end of August, AHP’s clinical pharmacists will be offering on-site provider visits to provide up-to-date, objective evidence focusing on outpatient medication management topics. These visits are: • Typically 10-15 minutes, based on providers’ schedules • 1:1 or in group provider settings, whichever is more convenient • Intended to be interactive- the clinical…

Read More ›

July 20th, 2018 | Pharmacy Pearls

This edition of Pharmacy Pearls discusses some of the nuances associated with selecting a urinary antispasmodic for incontinence, including a brief comparison of safety, tolerability, and approximate cost. Additionally, we are featuring a new section of Pharmacy Pearls called “Clinical Pharmacist Medication Management Highlight.” This will be a section where we gather examples from clinical…

Read More ›

May 17th, 2018 | Pharmacy Pearls

This edition of Pharmacy Pearls presents an equivalent dose chart for those providers wishing to switch patients from Lyrica to gabapentin to save patients money. Additionally, it contains information about the incidence of reactions to the Shingrix vaccine, information about the costs of different testosterone dosage forms, and an update about a new follow-on rapid-acting…

Read More ›

April 2nd, 2018 | Pharmacy Pearls

As discussed in the last Pharmacy Pearls “Less Expensive Inhaler Now Available,” switching patients to RespiClick will help AHP realize significant savings as well as help patients with their out-of-pocket costs. The patient education handout below can be provided to patients making the switch to ensure that they use their new inhaler correctly.

March 5th, 2018 | Network NewsNewsPharmacy Pearls

Opportunity to offer a less expensive generic maintenance inhaler to patients: The first generic ICS/LABA inhaler, fluticasone/salmeterol RespiClick®, was FDA approved in 2017. Current review of inhaler prescribing suggests the potential to realize a minimum of $900,000 savings across the network in 2018 by switching 25% of brand ICS/LABA inhalers to the generic product. Additionally,…

Read More ›